Medtronic agrees to acquire Lazarus Effect to expand its neurovascular business

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - handshake

Medtronic agreed to acquire Lazarus Effect, a medical device company with an acute ischemic stroke product that is approved in Europe but not in the U.S. The deal, which is subject to customary closing conditions, is an all-cash transaction valued at $100 million.

Lazarus Effect will be  included in Medtronic’s neurovascular division within the restorative therapies group. On Aug. 31, Medtronic acquired  Medina Medical, a medical device company developing a device to treat cerebral aneurysms that is also now in Medtronic’s neurovascular division.

Lazarus’s nitinol-mesh cover device folds over a stent retriever during clot retrieval, wraps around the stent with the clot inside and captures material during removal from a blood vessel. European regulators approved the device in November 2014.

The mesh cover is intended to fit with Medtronic’s Solitaire stent retriever, which is FDA-approved for use in the flow restoration of patients with ischemic stroke due to large intracranial vessel occlusion.

In June, the American Heart Association and American Stroke Association released stroke treatment guidelines that recommend using stent retrievers in conjunction with intravenous tissue plasminogen activator therapy for eligible patients.

Approximately 240,000 patients in the U.S. are eligible for treatment with a stent retriever each year after suffering an acute ischemic stroke, although Medtronic noted only 13,000 stent retriever procedures were performed in the U.S. in 2014.

Medtronic expects the deal to be earnings neutral in fiscal year 2016 and meet its long-term financial metrics for acquisitions.

In addition to the Lazarus Effect and Medina Medical deals, Medtronic has also acquired a few other companies recently, including  CardioInsightAptus EndosystemsRF Surgical Systems and Twelve.